Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody

NCT00431275 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

85

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

DRUG: CP-675,206
DRUG: CP-675,206

Sponsor

AstraZeneca